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Health Needs of HIV-Infected Women in the United States:
Insights from The Women Living Positive Survey
Kathleen E. Squires, M.D.,1 Sally L. Hodder, M.D.,2 Judith Feinberg, M.D.,3 Dawn Averitt Bridge,4
Staats Abrams,5 Stephen P. Storfer, M.D.,6 and Judith A. Aberg, M.D.7
Abstract
The objective of this study was to describe attitudes, opinions, and perceived health needs of HIV-infected
women in the United States. In this cross-sectional study, women were invited to participate in the Women
Living Positive survey, a structured interview instrument with 45 questions. Collected data were deidentified
and the margin of error was calculated as four percentage points. Incoming toll-free phone interviews were
conducted from December 21, 2006, through March 14, 2007 among subjects recruited from a U.S. national
network of AIDS counseling centers. Seven hundred HIV-infected women (43% African American, 28.5% His-
panic, 28.5% Caucasian; median age, 42.5 years) receiving combination antiretroviral therapy for 3 years or more
replied to recruitment flyers. Overall, 55% of survey participants had never discussed gender-specific HIV
treatment issues with their HIV care providers. Of the 45% who did discuss these issues, almost all (96%) were
satisfied. On average, one-third of the women had seen three or more providers since beginning HIV treatment;
43% indicated they had switched providers because of communication issues. Among women who had been or
were pregnant at the time of the survey (n = 159), more than half (57%) had not had pre-pregnancy discussions
with their HIV provider about the most appropriate HIV regimens for women attempting to become pregnant.
Significant communication gaps exist between HIV-infected women and their providers when discussing gen-
der-specific treatment issues. These data highlight a need for U.S. health care providers to incorporate discussion
of gender-specific issues, including preconception and reproductive counseling, into management strategies for
HIV-infected women.
Introduction
Worldwide, women represent half of all adults livingwith HIV and AIDS.1 Over the past two decades there
has been an increase in the proportion of women living
with HIV/AIDS in the United States. The latest estimates
from the Centers of Disease Control indicate that of the more
than 1.1 million people living with HIV in the United States
in 2006, 278,400 were women.2 By this account women rep-
resent approximately one quarter of the U.S. HIV-infected
population, a significant increase from the 13% reported just a
decade earlier in 1994.3
Many HIV-infected women express the desire to bear chil-
dren, and the use of highly active antiretroviral therapy during
pregnancy, alongwith appropriate use of caesarean section and
avoidance of breast-feeding, have resulted in significantly de-
creased perinatal acquisition rates to less than 2% in the United
States.4 Yet, there are scant data on the effectivenesswith which
medical providers address potential pregnancy in HIV-infected
women. In a recent cross-sectional study of 181 predominantly
AfricanAmericanHIV-infectedwomen, 67% reported a general
discussion about pregnancy and HIV with their primary health
care provider, whereas 31% reported a personalized discussion
about future childbearing plans. Of these personalized discus-
sions, 64% were patient initiated.5 In light of the rising preva-
lence of HIV/AIDS among women in the United States, it is
essential to understand the current attitudes, perceptions and
health needs of this patient population. In addition, HIV
disease, as well as antiretroviral therapy, may affect women
differently than men and HIV-infected women face a unique
1Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
2University of Medicine and Dentistry of New Jersey, Newark, New Jersey. 3University of Cincinnati College of Medicine, Cincinnati,
Ohio.
4The Well Project, Nellysford, Virginia.
5GfK Roper Public Affairs & Media, New York, New York.
6Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.
7New York University at Bellevue Hospital Center, New York, New York.
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set of health and psychosocial issues thatmay alter the course of
their treatment and disease. Despite these anticipated differ-
ences, few studies have explored the gender-specific health
needs of HIV-infected women. The Women Living Positive
(WLP) survey (Supplementary Material; Supplementary data
are available online at www.liebertonline.com/apc) provides
direct feedback fromwomen about the communication barriers
with their health care providers regarding important issues,
including preconception and reproductive counseling.
Methods
The WLP survey was designed with the input of HIV-
infected women to explore their attitudes and behaviors as
they relate to gender-specific health care needs, patient–health
care provider communications and preconception counsel-
ing in the United States. A 15-min telephone survey was de-
signed to effectively describe some aspects of the patients’
relationships with HIV health care providers, treatment pri-
orities, reproductive health issues (including questions
about pregnancy and family planning) and emotional aspects
of living with HIV. The survey consisted of a series of eligi-
bility questions as well as 45 topic-specific questions. Re-
spondents were anonymously interviewed by telephone from
December 21, 2006, through March 14, 2007, by GfK Roper
Public Affairs & Media (New York, NY), a public opinion
polling firm. The survey was funded and managed by Boeh-
ringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, CT) in
consultation with The Well Project (Atlanta, GA; www
.thewellproject.org), a nonprofit organization for women
affected by HIV.
Study investigators sought a study population that would
accurately reflect the regional, racial, and ethnic demo-
graphics of HIV-infected women in the United States. Parti-
cipants were recruited via flyers from a diverse group of 29
AIDS information, counseling, and treatment centers across
the United States, which directed HIV-infected women to call
a toll-free number. Response rates could not be determined
because of the recruitment method. Participants were desig-
nated to one of three possible groups: Caucasian; Hispanic or
African American. The African American sample consisted of
respondents who identified themselves as ‘‘African American
or black, not of Hispanic origin,’’ the Caucasian sample con-
sisted of respondents who identified themselves as ‘‘Cauca-
sian or white, not of Hispanic origin,’’ and Hispanic women
self-identified as Hispanic without membership in either of
the other groups. Women belonging to other racial/ethnic
groups were excluded. Interviews were conducted in Spanish
and English, depending on the participant’s preference.
Inclusion criteria included: HIV seropositivity by self-
report, receipt of combination antiretroviral therapy for at
least 3 years and older than 18 years. Women who qualified
for the survey were compensated $25 for their time. Partici-
pants were surveyed anonymously; upon completion each
was assigned a code to provide to the counseling center’s
administrator for compensation. Descriptive statistics were
performed on responses; the margin of error was four per-
centage points. Data were weighted by census regions and
ethnicity/race tomatch the demographic profile of adult HIV-
infected women in the United States.
Results
The sample comprised 700 HIV-infected women: 200
Caucasian; 200 Hispanic and 300 African American. The
median age was 42.5 years (range, 21–69 years; Table 1).
Participants had been aware of their HIV status for a mean of
10.6 years and were receiving combination antiretroviral
therapy for a mean of 8.1 years. Geographic distribution was
as follows: 16%, West; 21%, Midwest; 33%, South; and 30%,
Northeast. Thirty-nine percent of participants had children.
Perceived gender issues
Although nearly half (46%) felt that their disease af-
fected them differently than men, a majority (55%) had never
Table 1. Demographic Information of HIV-Infected Women in the Study
% Participants
Variable
Total sample
(n = 700)
Caucasian
(n = 200)
Hispanic
(n = 200)
African American
(n = 300)
Marital status
Married/living with partner 28 35 37 23a
Single 38 26 26 45a
Separated/divorced 25 29 21 25
Widowed 9 9 16 7
Education
High school graduate or less 61 51 69 61
Some college 23 30 17 23
College graduate or more 12 16 10 11
Age, y
Under 35 19 20 14 20
35–44 39 36 47a 37
45 and older 42 44 37 43
Years with identified HIV infection, mean 10.6 11.3 10.1 10.6
Years on antiretroviral medication, mean 8.1 8.9a 7.6 8.0
Have child/children 39 30a 40 41
Caregiver (net) 52 44 58 52
aSignificantly different from the other two subgroups at the 95% confidence level.
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discussed possible gender-based differences in treatment re-
sponse with their practitioners. Caucasian and African
American women were less likely than Hispanic women to
have discussed this issue with their HIV health care provider
(58% and 61% versus 34%, respectively; p < 0.05). Women
with male HIV health care providers were significantly less
likely than women with female providers to have discussed
this topic (41% versus 51%, respectively; p < 0.05). Of the 45%
who did have this discussion with their providers, almost all
(96%) were satisfied with the answers they received. Of note,
on average one third of the women had seen three or more
providers since they started receiving treatment for HIV, and
43% indicated that they had switched providers because of
communication issues.
Reproductive, childbearing, and caregiver issues
TheWLP survey also revealed a significant communication
gap between HIV-infected women and their practitioners on
reproductive issues. Of the 227 women who had been preg-
nant but were not pregnant at the time of the survey or those
who would consider pregnancy, approximately half (48%)
were never asked by their health care provider if they had or
were considering having children. Of women who had been
or were pregnant or were thinking about getting pregnant at
the time of the survey (n = 239), 57% had not discussed ap-
propriate treatment options with their practitioners before
becoming pregnant. Moreover, of those who were currently
pregnant or who had been pregnant (n = 159), only 64 (42%)
had discussed their pregnancy and appropriate HIV treat-
ment options with their HIV health care provider prior to
becoming pregnant. Additionally, 42% of those who were
currently pregnant or who had been pregnant were either
‘‘not very aware’’ or ‘‘not at all aware’’ of the treatment op-
tions for pregnant women with HIV.
Survey responses demonstrated a dichotomy between
perceived societal views and the respondent’s personal views
on childbearing among HIV-infected women. Although a
majority—61% overall: 61% African American, 62% Cauca-
sian, 59% Hispanic—personally felt that they could have
children with the appropriate medical care, 59% believed that
society strongly urges them not to have children. Caucasian
women were significantly more likely than Hispanic women
to express this perception (67% versus 53%, respectively;
p < 0.05). Additionally, HIV-infected women living in the
South were more likely than those in the Northeast or Mid-
west to experience this societal stigma (66% versus 52% and
55%, respectively; p< 0.05). HIV-infected women who re-
ceived care from a nurse practitioner or physician assistant
were significantly less likely to note this attitude than those
treated by an infectious disease specialist or family medicine/
general practitioner (48% versus 62% and 62%, respectively;
p < 0.05).
Thirty-nine percent of the participants had children in their
household, and 52% identified themselves as caregivers. In
all, 43% reported that living with HIV has made it more dif-
ficult for them to take care of their families, including 53% of
Hispanics, 40% of African Americans and 45% of Caucasians
( p< 0.05). Regionally, more women in the South versus the
Northeast reported that living with HIV has made it more
difficult for them to take care of their families (50% versus
37%, respectively; p < 0.05).
Other issues of concern
Fifty-nine percent felt that their culture, ethnicity or lan-
guage has an effect on the care that they receive. Hispanic and
African American womenwere more likely to report this than
Caucasian women (Fig. 1). Women in the South were also
more likely than those in the West or Northeast to feel that
their culture, ethnicity or language affects care. However, a
majority of HIV-infected women in the survey—regardless of
their ethnicity—shared similar treatment priorities, indicating
that factors such as suppressing viral load, achieving long-
term success with medication and being able to live normal
lives were important aspects of their HIV treatment (Fig. 2).
Overall, HIV-infected women who wanted additional
support beyond what their practitioners could provide indi-
cated they found it through support groups, therapists, fam-
ily, and friends. Caucasian women primarily identified
therapists as sources of additional support (38% compared
with 25% and 23% for Hispanic and African American par-
ticipants, respectively; p < 0.05), while Hispanic and African
American participants primarily identified support groups.
Source of support varied by geographic location, with women
in the Midwest and Northeast more likely to get additional
support from a support group or a therapist while those in the
South were more likely to get this support from family and
friends (Fig. 3).
Seventy-three percent overall indicated that living with
HIV has caused them to struggle ‘‘a great deal’’ or ‘‘some-
what’’ in managing their daily lives (70% of African Ameri-
can, 79% of Caucasian, and 78% of Hispanic participants).
Twenty-seven percent described have often experienced five
or more feelings commonly associated with depression, with
one third experiencing changes in sleep patterns, loss of en-
ergy, unexplained aches or pains, feelings of sadness or worry
and anxiety. Although 58% indicated they were comfortable
talking to their providers about their depression-related feel-
ings, women in the South were significantly less likely to feel
comfortable than those in the rest of the country (47% versus
58%, respectively; p< 0.05).
Discussion
Despite the fact that women now comprise more than one
fourth of all persons living with HIV in the United States, the
data from the WLP survey suggest that there are enormous
opportunities for improved communication between health
care providers and HIV-infected women regarding gender-
based issues, particularly as they relate to management of
HIV infection in anticipation of and/or during pregnancy.
This survey provided a platform for a broad selection
of women with HIV to describe their concerns regarding
patient–provider communication, and brought to light sev-
eral important issues. The fact that less than half of the par-
ticipants had discussed gender-based issues with their health
care providers may relate to lack of experience or comfort
among providers in raising these issues. It is also possible that
HIV practitioners do not anticipate discussing family plan-
ning and pregnancy with their patients because of a general
lack of focus or priority on this subject, or an expectation that
this subject will be addressed by other health care providers.
Additionally, a lack of gender-specific knowledge on the part
of the provider may preclude such discussions. Although
there continues to be a relative lack of data on how treatment
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of HIV-infected women may differ from the data regarding
men, there has been amarked increase in the presentation and
publication of treatment studies in women in recent years.
Several pharmacokinetic studies have been performed in
pregnant women,6–8 and recent analyses of the Pregnancy
Registry data provide a measure of reassurance on the effects
of in utero antiretroviral exposure.9 Therefore, data are avail-
able to providers regarding safety and dosing of some anti-
retroviral agents in pregnant women. Data on optimal
combination antiretroviral therapy during pregnancy is lim-
ited; much of the information comes from mother-to-child
transmission-prevention trials. While these trials have clearly
established the efficacy of antiretroviral agents in preventing
HIV transmission, they provide only limited data on optimal
antiretroviral agent combinations for tolerability and efficacy
during pregnancy.
Although there is abundant evidence that pregnancy in
HIV-infected women is associated with successful outcomes
and low risk of mother-to-child transmission, the social
stigma surrounding this issue remains strong. Many HIV-
infectedmothers fear that the diseasewill gravely disrupt their
ability to raise their children. In theWLP survey, HIV-infected
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women commonly felt stigmatized by society. Women also
fear the possibility of losing their children and the likelihood
that their children will be ostracized if their mother’s HIV
status is disclosed.10 As a result of these concerns HIV-infected
women, particularly those who serve as caregivers, may keep
their HIV status confidential for as long as possible and may
even be hesitant to seek early medical care.11 These factors
may explain, in part, why a significant proportion of HIV-
infected women in the United States are diagnosed with
HIV or seek treatment late in the course of their disease.12
In addition to fears over social stigmatization, factors such
as poverty, barriers that affect access to health care (such as
lack of medical insurance or competing subsistence needs),13
cultural and language barriers may hinder early diagnosis
and treatment.12 HIV providers must recognize that these
important barriers exist and proactively address them with
their patients. AnHIV providermay be one of the few persons
with whom an HIV-infected woman may frankly discuss the
implications and impact of HIV infection on their family re-
sponsibilities.
Studies of recently approved antiretroviral agents show
low participation rates by nonpregnant women, with 10–12%
of treatment experienced women enrolling in studies14–18 and
higher rates of participation in treatment-naı¨ve trials.19,20 As a
result, none of these randomized prospective trials have been
powered to assess outcomes in men versus those in women. In
the HEAT20 and CASTLE19 trials, two studies assessing com-
bination antiretroviral therapy in treatment-naı¨ve patients,
women represented 18% and 31% of participants, respectively,
and neither efficacy nor safety results were stratified by gender.
A review from the federally-funded Adult AIDS Clinical Trials
Group (ACTG) suggests that demographic factors such as a
patient’s ethnicity and geographic location may limit study
enrollment more than specific trial exclusionary criteria. At the
time of the ACTG reviewAfrican American women comprised
more than 50% of the total HIV-infected female population in
the United States, but accounted for less than 25% of women
entering the ACTG trials. Furthermore, relative to the regional
prevalence of HIV/AIDS among women, fewer women from
the Southeast and Mid-Atlantic regions enrolled in these trials
compared with the rest of the country.21
One study thatwas powered to compare safety and efficacy
outcomes in men and women was the recently presented
Gender, Race, and Clinical Experience (GRACE) trial. In this
study of 287 women and 142 men, virologic response by an
intent-to-treat analysis was higher in men (58.5%) than wo-
men (50.9%).22 However, a greater proportion of HIV-infected
women compared with men prematurely discontinued from
the study; after accounting for this difference, rates of viro-
logic response rates among men and women were similar.22
Although multiple reasons were given for discontinuations in
GRACE, the data suggest that womenmay have unique needs
that must be addressed to ensure retention in care.
Receiving an HIV diagnosis, coping with the disease on a
day-to-day basis, and living with fears and concerns
throughout the course of the disease can place a substantial
psychological burden on HIV-infected patients. Although our
study found that 27% of participants had five or more feelings
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commonly associated with depression, other studies have
reported even higher rates of depression. In the HIV Epide-
miology Research Study (HERS), 42% of the 765 HIV-positive
women enrolled had chronic depressive symptoms,23 while
50% of the 2058 HIV-positive study participants in the Wo-
men’s Interagency HIV Study (WIHS) had symptoms of
clinical depression.24 Further evidence suggests that women
living in rural areas are at greater risk for developing de-
pression because characteristics of rural environments, such
as physical isolation and concerns over social stigma, may
limit their ability to or the likelihood of seeking help.25 Re-
gardless of differences between sociodemographic groups,
rates of depression have been consistently higher amongHIV-
infected women collectively compared with HIV-infected
men.25 Chronic depression also has been linked to higher
mortality rates in HIV-infected women. In the HERS cohort
chronically depressed HIV-positive women were twice as
likely to die compared with those with limited or no depres-
sive symptom.23 Therefore, routine screening for depression
and other psychological illnesses should be incorporated into
the disease management plan for all HIV-infected women,
and adequate medication and counseling services should be
offered to those who meet the criteria for clinical depression.
Sociodemographic factors affect the manner in which HIV-
infected women receive support from the community. Social
support and coping mechanisms are vital parts of overall
disease management. Adequate social support can influence
psychological well-being,26,27 improve quality of life,28 and
facilitate factors such as medication adherence, which may
ultimately determine the progression of HIV disease.29
Our understanding of the unique health concerns of HIV-
infected women in the United States is slowly increasing. It is
imperative that this knowledge is successfully incorporated
into clinical practice. Women now constitute roughly 25% of
the individuals in the US in whom a new diagnosis of HIV is
made.3 Our data suggest that much remains to be accom-
plished in ensuring optimal care for women with HIV. Many
HIV care providers still do not incorporate a discussion of
gender-specific issues into patient visits. The results of the
WLP survey indicate that practitioners should proactively
discuss issues such as family and reproductive planning with
their HIV-infected patients. HIV providers should encourage
open discussions about other treatment-related, psychosocial,
and emotional aspects of HIV disease. At this point in the
history of HIV management providers are not simply pre-
venting death but are implementing long-term treatment
strategies to enable patients to live long and fulfilling lives.
This goal can only be achieved for HIV-infected women
through careful attention to gender-specific issues and by
establishing an environment for open communication. The
shortcomings in clinical practice perceived by HIV-infected
women in the WLP survey could be addressed by offering
training for HIV health care providers on gender-specific is-
sues and how to better communicate with their patients about
important issues, such as family planning and childbearing.
Acknowledgments
This study was funded by Boehringer Ingelheim Pharma-
ceuticals, Inc. and developed in collaboration with The Well
Project.
K.S., S.H., J.A., J.F., S.S., D.A.B., and S.A. had full access to
all the data in the study and take full responsibility for the
integrity of the data and the accuracy of the data analysis.
Study concept and design: S.S., S.A., D.A.B. Study conduct
and data collection and management: S.A. Data analysis and
interpretation: K.S., D.A.B., S.A., J.A.A., J.F., S.H., S.S.
Manuscript preparation and critical review: K.S., D.A.B., S.A.,
J.A.A., J.F., S.H., S.S. Manuscript approval: K.S., D.A.B., S.A.,
J.A.A., J.F., S.H., S.S. We acknowledge Devanshi Amin,
Pharm.D., for her editorial assistance with the preparation of
this report and Ann Wainwright, Boehringer Ingelheim
Pharmaceuticals, Inc., for her support in the execution of the
survey. We are grateful to all the survey participants for their
time and energy.
Author Disclosure Statement
Dr. Kathleen Squires, Dr. Sally Hodder, Ms. Dawn Averitt
Bridge, andMr. Staats Abrams are consultants for Boehringer
Ingelheim Pharmaceuticals, Inc. and Dr. Stephen Storfer
is employed by Boehringer Ingelheim Pharmaceuticals,
Inc. Drs. Judith Aberg and Judith Feinberg have received
honoraria from Boehringer Ingelheim Pharmaceuticals, Inc.
for participation in advisory boards.
References
1. UNAIDS. Worldwide HIV and AIDS Statistics. 2009.
www.avert.org/worldstats.htm (Last accessed February 28,
2011).
2. HIV prevalence estimates—United States, 2006. MMWR
Morb Mortal Wkly Rep 2008;57:1073–1076.
3. Update: AIDS among women—United States, 1994. MMWR
Morb Mortal Wkly Rep 1995;44:81–84.
4. Cooper ER, Charurat M, Mofenson L, et al. Combination
antiretroviral strategies for the treatment of pregnant HIV-1–
infected women and prevention of perinatal HIV-1 trans-
mission. J Acquir Immune Defic Syndr 2002;29:484–494.
5. Finocchario-Kessler S, Dariotis JK, Sweat MD, et al. Do HIV-
infected women want to discuss reproductive plans with
providers, and are those conversations occurring? AIDS
Patient Care STDs 2010;24:317–323.
6. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure
with an increased dose during pregnancy. J Acquir Immune
Defic Syndr 2008;49:485–491.
7. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus
low-dose ritonavir in pregnancy: pharmacokinetics and
placental transfer. AIDS 2007;21:2409–2415.
8. Hirt D, Urien S, Ekouevi DK, et al. Population pharmaco-
kinetics of tenofovir in HIV-1–infected pregnant women and
their neonates (ANRS 12109). Clin Pharmacol Ther 2009;85:
182–189.
9. Squires K, Olmscheid B, Guyer B, Zhang S. TDF-containing
antiretroviral regimens in pregnancy: Findings from the
Antiretroviral Pregnancy Registry. In: 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy
(ICAAC); 2009. San Francisco: September 12–15, 2009.
10. Marlink R, Kao H, Hsieh E. Clinical care issues for women
living with HIV and AIDS in the United States. AIDS Res
Hum Retroviruses 2001;17:1–33.
11. Sowell RL, Seals B, Moneyham L, Guillory J, Demi A, Cohen
L. Barriers to health-seeking behaviors for women infected
with HIV. Nursingconnections 1996;9:5–17.
284 SQUIRES ET AL.
12. Squires KE. Gender differences in the diagnosis and treat-
ment of HIV. Gend Med 2007;4:294–307.
13. Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection
in women in the United States: Status at the Millennium.
JAMA 2001;285:1186–1192.
14. Merck & Co, Inc ISENTRESS (raltegravir) [full prescribing
information]. www.merck.com/product/usa/pi_circulars/
i/isentress/isentress_pi.pdf (Last accessed April 22, 2010).
15. Pfizer Labs SELZENTRY (maraviroc) tablets [full pre-
scribing information]. http://us.gsk.com/products/assets/
us_selzentry.pdf (Last accessed April 22, 2010).
16. Boehringer Ingelheim Pharmaceuticals, Inc APTIVUS (ti-
pranavir) capsules and oral solution [full prescribing informa-
tion]. http://bidocs.boehringer-ingelheim.com/BIWebAccess/
ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing+
Information/PIs/Aptivus/10003515+US+ 01.pdf (Last ac-
cessed April 22, 2010).
17. Tibotec Therapeutics INTELENCE (etravirine) tablets
[full prescribing information]. www.intelence-info.com/
intelence/assets/pdf/INTELENCE_PI.pdf Accessed 22 April
2010,
18. Tibotec Therapeutics PREZISTA (darunavir) tablet, film
coated for oral use [full prescribing information]. http://
www.prezista.com/prezista/documents/us_package_insert
.pdf Accessed 22 April 2010,
19. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-
daily atazanavir/ritonavir compared with twice-daily lopi-
navir/ritonavir, each in combination with tenofovir and
emtricitabine, for management of antiretroviral-naive HIV-
1-infected patients: 96-week efficacy and safety results of
the CASTLE study. J Acquir Immune Defic Syndr 2008;53:
323–332.
20. Smith KY, Patel P, Fine D, et al. Randomized, double-blind,
placebo-matched, multicenter trial of abacavir/lamivudine
or tenofovir/emtricitabine with lopinavir/ritonavir for ini-
tial HIV treatment. AIDS 2009;23:1547–1556.
21. Cotton DJ, Finkelstein DM, He W, Feinberg J. Determinants
of accrual of women to a large, multicenter clinical trials
program of human immunodeficiency virus infection. The
AIDS Clinical Trials Group. J Acquir Immune Defic Syndr
1993;6:1322–1328.
22. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based out-
comes of darunavir-ritonavir therapy: a single-group trial.
Ann Intern Med 2010;153:349–357.
23. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality,
CD4 cell count decline, and depressive symptoms among
HIV-seropositive women: longitudinal analysis from the HIV
Epidemiology Research Study. JAMA 2001;285:1466–1474.
24. Barkan SE, Melnick SL, Preston-Martin S, et al. The Wo-
men’s Interagency HIV Study. WIHS Collaborative Study
Group. Epidemiology 1998;9:117–125.
25. Moneyham L, Murdaugh C, Phillips K, et al. Patterns of risk
of depressive symptoms among HIV-positive women in the
southeastern United States. J Assoc Nurses AIDS Care 2005;
16:25–38.
26. Kempf MC, McLeod J, Boehme AK, et al. A qualitative study
of the barriers and facilitators to retention-in-care among
HIV-positive women in the rural southeastern United States:
Implications for targeted interventions. AIDS Patient Care
STDs 2010;24:515–520.
27. Vyavaharkar M, Moneyham L, Corwin S, Saunders R, An-
nang L, Tavakoli A. Relationships between stigma, social
support, and depression in HIV-infected African American
women living in the rural Southeastern United States.
J Assoc Nurses AIDS Care 2010;21:144–152.
28. Sowell RL, Seals BF, Moneyham L, Demi A, Cohen L, Brake
S. Quality of life in HIV-infected women in the south-eastern
United States. AIDS Care 1997;9:501–512.
29. Vyavaharkar M, Moneyham L, Tavakoli A, et al. Social
support, coping, and medication adherence among HIV-
positive women with depression living in rural areas of the
southeastern United States. AIDS Patient Care STDS 2007;
21:667–680.
Address correspondence to:
Kathleen Squires, M.D.
Jefferson Medical College
Division of Infectious Diseases
211 South 9th Street, Suite 210
Philadelphia, PA 19107
E-mail: Kathleen.Squires@jefferson.edu
HEALTH NEEDS OF HIV-INFECTED WOMEN 285

